Aktuella utlysningar, vecka 39, 2023
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
The Knut and Alice Wallenberg Foundation
- The Wallenberg Foundation Postdoctoral Fellowships at Nanyang Technological University Singapore
The Knut and Alice Wallenberg Foundation has established a long-term postdoctoral fellowship program at Nanyang Technological University (NTU), Singapore. The purpose of the program is to bring outstanding young Swedish scientists to NTU for two years of postdoctoral research and studies. The program is open for all disciplines at NTU. The Postdoctoral Fellows are given the opportunity to participate in a broad range of interdisciplinary activities and programs that characterize NTU’s approach to research and education.
- The Wallenberg Foundation Scholarship Program for Postdoctoral studies at Massachusetts Institute of Technology and Broad Institute
The Knut and Alice Wallenberg Foundation has established a long-term scholarship program for postdoctoral studies at Massachusetts Institute of Technology (MIT) and Broad Institute. The purpose of the program is to bring outstanding young Swedish scientists to MIT for two years of postdoctoral studies. The program is open for all disciplines at MIT and Broad Institute. The Postdoctoral Fellows are given the opportunity to participate in a broad range of interdisciplinary activities and programs that characterize MIT and Broad’s approach to research and education.
- The Wallenberg Foundation Postdoctoral Scholarship at Stanford University, USA
The Knut and Alice Wallenberg Foundation has established a long-term postdoctoral scholarship program at Stanford University. The purpose of the program is to bring outstanding young Swedish scientists to Stanford University for one to two years of postdoctoral study and research. The program is open for all disciplines. The Postdoctoral Fellows are given the opportunity to participate in a broad range of interdisciplinary activities and programs that characterize Stanford’s approach to research and education.
After completing their postdoctoral visit at either of these universities/institutes, the Fellows/Scholars will be supported upon their return to Sweden and use their experience for the benefit of Sweden.
N.B. Application period begins October 18.
Closing date: November 15, 2023
Invitation to nominate to the Kavli Prize 2024
Nominations for the 2024 Kavli Prize opened July 1, 2023. On behalf of The Norwegian Academy of Science and Letters, I cordially invite you to help identify the next Kavli Prize Laureates, scientists whose basic research has fundamentally transformed astrophysics, nanoscience and neuroscience – the big, the small, and the complex. You may do so by nominating directly, encouraging others at your institution to nominate or by spreading the word within your networks. You are also welcome to share this letter with anyone you feel might like to nominate.
Nominations may be submitted through October 1, 2023, at our website.
The Kavli Prize awards USD 1 million prizes in each of the three scientific fields. The announcement will be made June 12, 2024.
The Kavli Prize is committed to recognizing breakthrough science worldwide. We encourage nominators to be mindful of the full diversity of the scientific enterprise and be attuned to gender, race and ethnicity, geographical region, and institutional diversity. As you consider your nominations, below is some additional information to keep in mind:
- Only breakthroughs in astrophysics, nanoscience and neuroscience are considered.
- Multiple nominations recognizing different breakthroughs are permitted.
- Anyone can nominate, but self-nominations are not accepted.
I hope that you will take the opportunity to help our selection committees identify the next Kavli Prize Laureates.
If you have any questions, please do not hesitate to contact Mr. Eirik Lislerud, Project Manager, at The Norwegian Academy of Science and Letters via email.
Europeiska anslag
Call for proposals on patient-centered and patient-driven care in rheumatic and musculoskeletal disorders
Foundation for Research in Rheumatology (FOREUM), CH
This supports research proposals focused on developing and implementing scientific research-based patient-centred and patient-driven approaches to improve the care and well-being of individuals living with RMDs. This call aims to stimulate impactful scientific research that revolutionizes the way care is delivered, ensuring that it is tailored to individual needs and supports long-term sustainability. Scientific proposals that address the following areas are encouraged:
•patient-centred care;
•patient-driven approaches;
•sustainable care models.
An individual proposal may be funded with up to a maximal amount of €600.000 for a three-year funding period.
Applications must involve partners from at least three different countries. Any given institution shall be allowed to lead on only one application. However, that institution, or its staff may participate in other projects as collaborators. The call shall be open to participants from EULAR membership countries. The Principal Investigator should come from a EULAR membership country.
Closing date 05 November 2023
- Closing date for Letter of intent: 05 November 2023
- Decisions on Letter of intent announced: 12 February 2024
- Closing date for full proposals: 14 April 2024
- Decisions on full proposals announced: 01 July 2024
Data partner call
European Health Data and Evidence Network, BE
This enables data partners in Europe to map their health data to the Observational Medical Outcomes Partnership common data model. The aim of the project is to standardise more than 100 million patient records across Europe and facilitate their use to enhance and accelerate research and healthcare decision-making for global benefit.
Data partners based in an EU member state or Horizon2020 associated country may apply.
Grants are worth up to €100,000 for each data partner.
Closing date 10 November 2023 (Forecast)
International grants
Biocodex Microbiota Foundation, FR
These support clinical or fundamental research projects focused on human gut microbiota related to health and disease. For the current round, projects must focus on the role of gut microbiota in the mechanisms of pain.
The grant is worth €200,000 over one to three years.
Closing date 30 November 2023
Osteology researcher grants
These support research on oral tissue regeneration. Topics may include:
•hard and soft tissue biology;
•novel bone and soft tissue substitute materials;
•local factors affecting oral tissue regeneration;
•systemic diseases with an impact on oral tissue regeneration;
•pharmacological aspects of oral tissue regeneration;
•inflammatory conditions, such as periodontitis and peri-implantitis.
Grants for advanced researchers are worth up to CHF 100,000 each for projects lasting up to two years. Grants for young researchers are worth up to CHF 30,000 each for projects lasting up to one year.
Closing date note Abstracts due every 15 June and 1 December; detailed applications open 1 March and 1 September and close 15 April and 15 October.
Working groups call - concepts for health and social care research for neurodegenerative diseases
EU Joint Programme - Neurodegenerative Disease Research (JPND), EU
This supports innovative, multi-disciplinary and multinational working groups in addressing the specific needs of patients and developing strategies to improve support for people at moderate, advanced and end of life stages of disease progression. Working groups must focus on one or several of the following neurodegenerative diseases:
•Alzheimer's disease and other dementias;
•Parkinson's disease and PD-related disorders;
•Prion diseases;
•motor neuron diseases;
•Huntington's disease;
•spinocerebellar ataxia;
•spinal muscular atrophy.
Working groups must be led by a coordinator from an institution from one of the following participating countries: Canada, France, Germany, Italy, Ireland, the Netherlands, Norway or Sweden. Working groups must include between six and 25 experts who may be from any country worldwide, but at least half of the participants of the working group must be from JPND countries. At least five countries must be represented in any working group.
Grants are worth up to €50,000 each for 12 months and cover meeting organisation and travel costs.
Closing date 13 December 2023 (Forecast)
Visiting professorships
Weizmann Institute of Science, IL
These support scientists from institutions of higher learning and research institutions in any country who wish to conduct research in Israel. The following professorships are available:
•Weston visiting professorships;
•Erna and Jakob Michael visiting professorships;
•Joseph Meyerhoff visiting professorships;
•Rosi and Max Varon visiting professorships;
•Morris Belkin visiting professorships.
Applicants must have achieved appropriate recognition in their fields of activity and hold the rank of full professor or equivalent in their home institutions.
Funding may include financial remuneration, travel costs and rent-free housing for two months to one year during the 2024 to 2025 academic year.
Closing date 31 December 2023
Amerikanska anslag
Federal Funding
NIH - Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01, R21 Clinical Trial Not Allowed)
Funding Opportunity ID: PAR-23-297 (R01), PAR-23-296 (R21)
Upcoming deadlines: Full applications – 7th January, 7th May, 7th September 2024 until 7th September 2026.
Abstract: The purpose of this Notice of Funding Opportunity (NOFO) is to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the ultimate goal of achieving sustained treatment-free remission.
More info: PAR-23-297: Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed) (nih.gov); PAR-23-296: Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed) (nih.gov)
NIH - Computationally-Defined Behaviors in Psychiatry (R01, R21 Clinical Trial Optional)
Funding Opportunity ID: PAR-23-305 (R21); PAR-23-307 (R01)
Upcoming deadlines: Full application – 1st November 2023
Abstract: This Notice of Funding Opportunity (NOFO) solicits applications for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function. These projects should focus on behavior in humans and test computational models in healthy, trans-diagnostic, unselected, or community samples. NIMH is particularly interested in the study of behavioral measures, models, and parameters that have the potential for back-translation from humans to animals, especially for pre-clinical therapeutics development, and in models that have the potential to be extended to clinical populations. To maximize prospects of back-translation and to provide a neurobiological foundation for future research, studies will need to consider behavioral models and parameters that are linked to the underlying neural processes that may be involved in their computation. Finally, in order to ensure ecological validity of behavioral assays, models derived from lab-based behavioral tasks will need to be tested for generalizability to behavioral data collected in a real-world setting.
More info: PAR-23-305: Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) (nih.gov), PAR-23-307: Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) (nih.gov)
NIH - Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01, R21 Clinical Trial Not Allowed)
Funding Opportunity ID: RFA-DA-25-016 (R01); RFA-DA-25-017 (R21)
Upcoming deadlines: Full applications – 14th August 2024 (R01); 13th August 2024 (R21)
Abstract: The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses.
This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.
Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
More info: RFA-DA-25-016: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) (nih.gov); RFA-DA-25-017: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) (nih.gov)
NIH - BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
Funding Opportunity ID: RFA-EY-23-001 (R21); RFA-NS-24-004 (R01)
Upcoming deadlines: Full applications – 19th January, 1st October 2024; 2nd June 2025; 20th January 2026 (R01); 18th June 2024; 17th June 2025; 15th June 2026 (R21).
Abstract: This NOFO seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range of modalities are appropriate including acoustic, chemical, electrical, magnetic, and optical, as well as the use of genetic tools.
Invasive or non-invasive approaches are sought that will enable large-scale recording and/or precise manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving animals. Applications are encouraged from any qualified individual, including chemists, physicists, engineers, theoreticians, materials scientists, and others from fields not typically involved with neuroscience research.
This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.
More info: RFA-EY-23-001: BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) (nih.gov); RFA-NS-24-004: BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) (nih.gov)
NIH - Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional)
Funding Opportunity ID: RFA-MH-24-330 (R01); RFA-MH-24-331 (R21); RFA-MH-24-332 (R34)
Upcoming deadlines: Full application – 22nd November 2023
Abstract: This Notice of Funding Opportunity (NOFO) invites applications to understand factors that impact uptake and adherent and persistent use of biomedical HIV prevention options, to inform and advance approaches to support choice and use among these options, and to understand and advance equitable delivery of biomedical HIV prevention options for cisgender and transgender women in settings where multiple prevention options are available.
This NOFO uses the R01 grant mechanism, while RFA-MH-24-331 uses the R21 mechanism and RFA-MH-24-332 uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applications with preliminary data and/or those including longitudinal analysis or proposing a large-scale clinical trial should consider using the R01 mechanism. Applicants proposing to develop and pilot test an intervention should consider the R34 mechanism.
.
More info: RFA-MH-24-330: Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional) (nih.gov); RFA-MH-24-331: Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional) (nih.gov); RFA-MH-24-332: Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional) (nih.gov)
Foundation
Angelman Syndrome Foundation, US – Open call for Research Proposals
Upcoming deadlines: 15th October 2023 (This call is repeated 2 times a year, October 15, and April 15)
Amount: Up to 200,000 USD.
Eligibility: Researchers from all countries are encouraged to apply.
Abstract: The Angelman Syndrome Foundation announces biannual calls for research proposals to be awarded in support of Angelman syndrome research.
The ASF Scientific Advisory Committee identified the following areas of unmet need in AS research. Priority will be given to the following topics:
- Projects studying or correcting the heterozygous effect of non-UBE3A genes in deletion.
- Projects studying the potential results of increasing UBE3A after therapies or for some subtypes of AS.
- Projects studying delivery of therapies and potential for improvement.
- Symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.
Website: Call for Proposals – Angelman Syndrome Foundation
The Hope Foundation, US – (SWOG) Cancer Research Network Early Exploration and Development (SEED) Fund
Upcoming deadlines: LOI – 1st December 2023 and 1st July 2024
Amount: Up to 50,000 USD. Indirect costs are limited to a rate of 25%.
Eligibility: Any SWOG member investigator eligible for NIH funding is encouraged to submit to this program. Awardees are expected to present their work at one or more semiannual SWOG group meetings and to adhere to Group policies and procedures as applicable to the project.
Abstract: The mission of SWOG Cancer Research Network is to significantly improve lives through cancer clinical trials and translational research. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG’s non-profit, philanthropic partner, The Hope Foundation for Cancer Research.
Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the National Clinical Trials Network (NCTN). These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology.
Website: SWOG Cancer Research SEED Fund - The Hope Foundation
Foundation Fighting Blindness (FFB), US - Program Project Award (PPA)
Upcoming deadlines: LOI – 12nd October 2023; Full application- 27 February 2024.
Amount: Upper: $2,500,000USD
Funding for this effort will be considered up to $500,000 per year up to five (5) years.
Eligibility: Open to all independent researchers.
Abstract: This award engages cross-disciplinary investigators to drive collaborative retinal degenerative disease research efforts. The PPA enables studies that are too large or technically complex for a single investigator to undertake in a reasonable amount of time and to address current knowledge and/or therapeutic gaps. The effort is unified around a single, well-articulated research hypothesis and clearly defined milestones relevant to the Foundation’s mission. The PPA award address knowledge gaps or therapeutic goals identified by The Foundation or an equally significant gap or goal approved by the Foundation.